戴纳基公布额外一年临床数据,显示治疗肌强直性营养不良1型药物Zeleciment Basivarsen在1/2期ACHIEVE试验中展现功能性改善

美股速递
Oct 07, 2025

戴纳基近日公布了其候选药物Zeleciment Basivarsen (Dyne-101)在治疗肌强直性营养不良1型(DM1)方面的额外一年临床数据。该数据来自1/2期ACHIEVE试验,结果显示患者出现功能性改善。

这项临床试验为期一年的追踪数据进一步证实了Zeleciment Basivarsen在治疗这种罕见遗传性疾病方面的潜在疗效。肌强直性营养不良1型是一种影响肌肉功能的遗传性疾病,目前缺乏有效的治疗选择。

ACHIEVE试验的最新数据为该药物的进一步开发提供了重要支持,也为DM1患者群体带来了新的治疗希望。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10